Corticosteroids infiltration

PreclinicalSmall molecule

CCentre Hospitalier Departemental Vendee

Corticosteroids infiltration is one of 14 small molecule programs targeting Arthropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthropathyActive, not recruiting

ArthropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Arthropathy

#DrugCompanyPhaseTrials

Marinol

Alnylam Pharmaceuticals

Enbrel

1 3

Cyklokapron

AAmring

Approved

—4

Vancocin

HHikma Pharmaceuticals LLC

Approved

—5

Naropin

FFresenius Kabi Oncology Ltd.

Prolia

1 7

Decadron

QQuince Therapeutics S.p.A.

Forteo

1 9

Botox

RRevance Therapeutics, Inc.

Phase 2

1 10

Cox-2 Inhibitor

SSeoul National University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Arthropathy1 trial

Care of AcromioClavicular Arthropathy in Manual Medicine Versus Corticosteroid Infiltration (ACAM)

Terminated·—·N/A·NCT03951480·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Corticosteroids infiltration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Corticosteroids infiltration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Corticosteroids infiltration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Departemental Vendee company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Departemental Vendee

Corticosteroids infiltration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Arthropathy1 trial

References

Drug Info

Quick Facts

Related News